Approval · Notice of Compliance 35517 · 2025
OZEMPIC: Notice of Compliance 35517
Issued June 11, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35517
- Date
- June 11, 2025
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a new manufacturing site and changes to manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OZEMPIC | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 0.68 MG per ML